Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
| Publication Date: |
2018-07-03
|
|---|---|
| Publisher: |
The American Association for Cancer Research (AACR)
|
| Print ISSN: |
1078-0432
|
| Electronic ISSN: |
1557-3265
|
| Topics: |
Medicine
|
| Published by: |
| _version_ | 1836398995199492096 |
|---|---|
| autor | Spring, L., Bardia, A. |
| beschreibung | Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999 |
| citation_standardnr | 6297177 |
| datenlieferant | ipn_articles |
| feed_id | 9363 |
| feed_publisher | The American Association for Cancer Research (AACR) |
| feed_publisher_url | http://www.aacr.org/ |
| insertion_date | 2018-07-03 |
| journaleissn | 1557-3265 |
| journalissn | 1078-0432 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | The American Association for Cancer Research (AACR) |
| quelle | Clinical Cancer Research |
| relation | http://clincancerres.aacrjournals.org/cgi/content/short/24/13/2981?rss=1 |
| search_space | articles |
| shingle_author_1 | Spring, L., Bardia, A. |
| shingle_author_2 | Spring, L., Bardia, A. |
| shingle_author_3 | Spring, L., Bardia, A. |
| shingle_author_4 | Spring, L., Bardia, A. |
| shingle_catch_all_1 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999 Spring, L., Bardia, A. The American Association for Cancer Research (AACR) 1078-0432 10780432 1557-3265 15573265 |
| shingle_catch_all_2 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999 Spring, L., Bardia, A. The American Association for Cancer Research (AACR) 1078-0432 10780432 1557-3265 15573265 |
| shingle_catch_all_3 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999 Spring, L., Bardia, A. The American Association for Cancer Research (AACR) 1078-0432 10780432 1557-3265 15573265 |
| shingle_catch_all_4 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor–positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981–3. ©2018 AACR . See related article by Shah et al., p. 2999 Spring, L., Bardia, A. The American Association for Cancer Research (AACR) 1078-0432 10780432 1557-3265 15573265 |
| shingle_title_1 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| shingle_title_2 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| shingle_title_3 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| shingle_title_4 | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| timestamp | 2025-06-30T23:35:56.101Z |
| titel | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| titel_suche | Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer |
| topic | WW-YZ |
| uid | ipn_articles_6297177 |